2018 looks set to be the year when the microbiome comes of age, clinically at least. Data are expected from early clinical studies using an array of approaches, which, if successful, will drive increased business activity in this area and increased interest from big pharma.
The microbiome’s proponents rate its prospects high. "The microbiome is one of two important fields for the future of medicine,"...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)